These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 20418203

  • 1. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A, Bernhard JC, Gross-Goupil M, Digue L, Ferriere JM.
    Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
    [Abstract] [Full Text] [Related]

  • 2. [mTOR inhibitors].
    Oya M.
    Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
    [Abstract] [Full Text] [Related]

  • 3. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE.
    Ann Clin Lab Sci; 2006 Jun; 36(3):283-93. PubMed ID: 16951269
    [Abstract] [Full Text] [Related]

  • 4. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
    Mulders P.
    BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial.
    N Engl J Med; 2007 May 31; 356(22):2271-81. PubMed ID: 17538086
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S, Medioni J, Aylllon J, Barrascourt E, Elaidi RT, Balcaceres J, Scotte F.
    Expert Rev Anticancer Ther; 2009 Jun 31; 9(6):705-17. PubMed ID: 19496707
    [Abstract] [Full Text] [Related]

  • 16. [Antitumoral effect of proliferation signal inhibitors].
    Dumortier J.
    Gastroenterol Clin Biol; 2009 Nov 31; 33 Suppl 4():S263-7. PubMed ID: 20004333
    [Abstract] [Full Text] [Related]

  • 17. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A, RECORD‐1 Study Group.
    Cancer; 2010 Sep 15; 116(18):4256-65. PubMed ID: 20549832
    [Abstract] [Full Text] [Related]

  • 18. [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma].
    Gennigens C, Sautois B, Jerusalem G.
    Rev Med Liege; 2010 Apr 15; 65(4):212-6. PubMed ID: 20499824
    [Abstract] [Full Text] [Related]

  • 19. Temsirolimus in renal cell carcinoma.
    Otto T, Eimer C, Gerullis H.
    Transplant Proc; 2008 Dec 15; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [Abstract] [Full Text] [Related]

  • 20. Targeting mTOR in renal cell carcinoma.
    Hudes GR.
    Cancer; 2009 May 15; 115(10 Suppl):2313-20. PubMed ID: 19402072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.